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Research Article
The use of routine blood tests to assist the diagnosis of
COVID-19 in symptomatic hospitalized patients
IT Parsons1,4 , AT Parsons2, E Balme3, G Hazell3, R Gifford4, M Stacey4, DR Woods4
and D Russell-Jones3
Abstract
Introduction: Specific patterns of blood test results are associated with COVID-19 infection. The aim of this study was
to identify which blood tests could be used to assist in diagnosing COVID-19.
Method: A retrospective review was performed on consecutive patients referred to hospital with a clinical suspicion of
COVID-19 over a period of fourweeks. The patient’s clinical presentation and severe acute respiratory syndrome
coronavirus 2 reverse-transcription polymerase chain reaction (SARS-CoV-2 RT-PCR) were recorded. The patients
were divided by diagnosis into COVID (COVID-19 infection) or CONTROL (an alternate diagnosis). A retrospective
review of consecutive patients over a further two-week period was used for the purposes of validation.
Results: Overall, 399 patients (53% COVID, 47% CONTROL) were analysed. White cell count, neutrophils and
lymphocytes were significantly lower, while lactate dehydrogenase and ferritin were significantly higher, in the COVID
group in comparison to CONTROL. Combining the white cell count, lymphocytes and ferritin results into a COVID
Combined Blood Test (CCBT) had an area under the curve of 0.79. Using a threshold CCBT of –0.8 resulted in a
sensitivity of 0.85 and a specificity of 0.63. Analysing this against a further retrospective review of 181 suspected COVID-
19 patients, using the same CCBT threshold, resulted in a sensitivity of 0.73 and a specificity of 0.75. The sensitivity was
comparable to the SARS-CoV-2 RT PCR.
Discussion: Mathematically combining the blood tests has the potential to assist clinical acumen allowing for rapid
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Introduction
The diagnosis of COVID-19, particularly in those not
requiring respiratory support, hinges on the detection
of severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) RNA by reverse-transcription polymer-
ase chain reaction (RT-PCR) following sampling of the
upper respiratory tract via a nasopharyngeal swab.
While a positive test for SARS-CoV-2 generally con-
firms the diagnosis of COVID-19, false-negative tests,
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from upper respiratory tract sampling, have been well
documented1 and could be as high as 20%.2–4 False
negatives can be due to the specific RT-PCR assay,
poor sampling technique, the type and quality of the
specimen obtained and the duration of the illness prior
to testing. There are significant consequences of miss-
ing diagnoses such as propagating viral transmission.
This is particularly important in the occupational man-
agement of key workers as well as non-infected
patients.
It has been established that COVID-19 infection is
associated with patterns of blood test results among
hospitalized patients. These include a raised lactate
dehydrogenase (LDH), inflammatory markers (e.g. fer-
ritin [FER], C-reactive protein [CRP], aminotransfer-
ases and d-dimers5,6) and lymphopenia. These blood
tests, at particular levels, have been associated with a
worse prognosis in COVID-19 patients7–9 and have
been shown to differentiate between those who are
SARS-CoV-2 RT-PCR negative and positive.10
However, this does not account for the proportion of
patients who are SARS-CoV-2neg but are considered to
have COVID-19 clinically. The aim of this study was to
assess if any routine COVID-19 blood tests7 could
improve diagnostic accuracy in conjunction with that
of the detection of SARS-CoV-2 RT-RCR following
upper respiratory tract sampling. Specifically, we
aimed to (1) identify how blood tests differ between
patients who are ultimately diagnosed with COVID-
19, and those who are not, in patients referred for pos-
sible COVID-19 and (2) attempt to mathematically
combine blood test results together to assess if this
could be used to support a diagnosis of COVID-19.
Method
A retrospective review was performed on all patients
consecutively referred to General Internal Medicine
(GIM) over a period of fourweeks at a UK NHS
District General Hospital. Patients were only retro-
spectively included if the referral stated a clinical sus-
picion of COVID-19 and consequently a COVID-19
PCR-RT swab had been taken. These included
Emergency Department (ED) referrals and direct gen-
eral practitioner referrals. Patients who presented to
the ED and who were sent home without admission
were excluded. Patients with nosocomial transmission
of SARS-CoV-2 were excluded unless the patient had
been discharged and represented with symptoms of
COVID-19.
The patient’s admission blood test results and radio-
graphic results were noted as well as any other blood
tests or scans performed within 48 h of admission (to
account for missed-off tests or haemolysed samples and
delays to initial diagnostic cross-sectional imaging).
The presence of positive blood cultures was noted
with coagulase-negative staphylococcal cultures
excluded if considered (at the time) to be secondary
to skin commensal contamination. Where duplicate
tests were performed, the admission results only were
included except for a chest computed tomography (CT)
scan which was used preferentially to a chest radio-
graph (CXR). Radiology results (CXR11 and CT
thorax12) were summated and categorized as being:
‘in keeping with COVID-19 related lung disease’ (e.g.
for CXR: ground glass opacities, with bilateral, periph-
eral, and lower lung zone distributions), ‘not in keeping
with COVID-19’ or ‘indeterminate’. Radiographic
results were taken directly from the reporting radiolo-
gist/radiographer’s report with no primary interpreta-
tion performed. Reports were specifically written as
being supportive, not supportive, or indeterminate for
a diagnosis of COVID-19. Other presenting symptoms
were also recorded. Symptoms were noted as per Wang
et al.5 namely: fever, fatigue, dry cough, anorexia,
myalgia, dyspnoea. Other presenting symptoms were
recorded and categorized.
The patient’s length of inpatient admission and out-
come were noted. The patients were divided on account
of their discharge diagnosis into COVID or
CONTROL. The COVID group were thought to
have a clinical diagnosis of COVID-19 which consid-
ered the symptoms, signs, radiology and SARS-CoV-2
RT PCR swab (Kingfisher flex nucleic acid extraction
system and ABI7500 Fast PCR machine; Thermo
Fisher, Waltham, Massachusetts, USA). The
CONTROL group were considered not to have
COVID-19 using the same criteria. The groups were
split based on the discharge diagnosis, using the clinical
notes or discharge summary alone, with no retrospec-
tive interpretation. The COVID and CONTROL
groups were compared. We also performed a subgroup
analysis of the COVID group based on the SARS-
CoV-2 RT-PCR result as detected (COVIDposRT-
PCRpos) or not detected (COVIDposRT-PCRneg).
Finally, we compared the COVIDposRT-PCRneg
group with the CONTROL group.
Due to the retrospective design, using anonymized
data, no ethical approval was necessary for this service
evaluation. Data were assessed for normality using the
Shapiro-Wilk test prior to data analysis. Nominal data
were compared using Fisher’s exact test and expressed
as percentages. Parametric continuous measures were
compared with Student’s t-test and expressed as mean
and standard deviation. A Sensitivity Index (SI), as
another measure of how much the distributions
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separated, was used to compare COVID and
CONTROL blood tests. The Sensitivity Index is
defined as (equation (1)):





where l and r2 denote the mean and variance, respec-
tively, of a distribution. A sensitivity threshold of
>0.35 was used. Receiver operator curves (ROC)
were performed on blood tests with significant
(P< 0.05) differences between groups. The sensitivity
and specificities were examined and the area under
the curve (AUC) recorded. The a level was set to
0.05. Parametric and non-parametric analyses were
performed using GraphPad Prism 8.0, GraphPad
Software, San Diego, California. Sensitivity and specif-
icity analysis were performed using Matlab,
Mathworks, Natick, Massachusetts. A combined
blood test was formulated and the AUC calculated.
This was validated on a further retrospective dataset
of 181 patients.
Results
A total of 399 patients (cohort 1), 229 male (57%) and
170 female (43%), were referred to the GIM team for
consideration of hospitalization, with suspected
COVID-19, over a four-week period from 11 March
2020 to 8 April 2020. A clinical diagnosis of
COVID-19 was made in 213 patients (53%) (COVID
group) following consideration of symptoms, radiolo-
gy, blood tests and a SARS-CoV-2 RT-PCR with 186
(47%) diagnosed with not having COVID-19 based on
the same considerations (CONTROL group).
A comparison of demographic details, in hospital mor-
tality, symptoms and length of admission can be
reviewed in Table 1. If less than 5% of patients had a
specific symptom recorded, it was classified as ‘other’.
The CONTROL group were significantly more likely
to have ‘other’ symptoms (P< 0.0001) which included
dizziness, sore throat, diarrhoea and/or vomiting, col-
lapse, anorexia, palpitations, urinary retention, consti-
pation, wheeze, hyperglycaemia, difficulty coping at
home, headache, photophobia and rashes.
Radiological (predominantly CXR) investigation
was significantly different in COVID vs. CONTROL
groups (P< 0.0001). Overall, 32% of patients in the
COVID group did not have radiology in keeping with
COVID-19, 18% were indeterminate, with 50% in
keeping with changes typical of COVID-19 lung dis-
ease. By comparison 68% of patients in the
CONTROL group had radiological findings not in
keeping with COVID-19, 19% were indeterminate
and 12% were in keeping with COVID-19.
Blood tests
A comparison of blood tests between COVID and
CONTROL can be reviewed in Table 2. In the
COVID group, 49/213 patients (23%) had an influenza
Table 1. A comparison of demographics and symptoms for all patients referred to General Internal Medicine with a potential
diagnosis of COVID-19 who were ultimately diagnosed with COVID-19 (COVID) or another diagnosis (CONTROL).
COVID (SD) CONTROL (SD) P value
Demographics
Male (%) 62 53
Female (%) 38 47 0.069
Age (years) 64.7 (18.1) 68.9 (19.5) 0.030
Death during admission (%) 20.1 5.9 <0.0001****
Length of admission (days) 5.8 (5.2) 4.8 (3.5) 0.059
Presenting symptoms
Cough (%) 55 40 <0.0001****
Fever (%) 51 35 0.0025**
Dyspnoea (%) 46 51 0.302
Fatigue (%) 9 4 0.090
Chest pain (%) 8 14 0.068
Myalgia (%) 6 6 >0.999
Confusion (%) 5 6 0.645
Falls (%) 4 5 0.46
Other (%) 9 45 <0.0001****
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A, influenza B and respiratory syncytial viral swab;
78/186 patients (42%) in the CONTROL group. All
swabs were negative except for one positive swab for
influenza A in the CONTROL group. The sensitivity
and specificity, in all patients, of the SARS-CoV-2
RT-PCR was 74.2% and 99.5%, respectively, in diag-
nosing COVID vs. CONTROL.
COVID-19 patients with a negative SARS-CoV-2
RT-PCR
A subgroup analysis was performed to further eluci-
date the patients who were COVIDposRT-PCRneg.
Overall, there were 51/213 (24%) patients who were
COVIDposRT-PCRneg but considered to have COVID
representing 13% (51/399) of all patients referred with
the suspicion of COVID-19 over the four-week collect-
ing period. In this group, 23/51 (45%) patients had
radiological findings suggestive of COVID-19, 5/51
(10%) had radiological findings which were indetermi-
nate for COVID-19 and 22/51 (43%) had radiological
findings not suggestive of COVID-19. In one patient,
no radiological investigation was taken. Overall, 28/51
(55%) had a new persistent cough and/or fever. In
three patients, symptoms were not recorded in the
referral database. Overall, 35/51 (67%) patients had
at least one of new persistent cough, new fever or
chest X-ray changes in keeping with COVID-19 with
12/51 (24%) patients having neither. In four patients,
the admission data were incomplete.
In comparing COVIDposRT-PCRneg patients with
the CONTROL patients, there was a significant differ-
ence in FER levels (CONTROL; 384 628 mg/L,
COVIDposRT-PCRneg; 985 1344 mg/L, P¼ 0.001).
COVIDposRT-PCRneg patients were significantly
more likely to have a radiological investigation in keep-
ing with COVID in comparison to CONTROL
(COVIDposRT-PCRneg 45%, CONTROL; 12%,
P< 0.0001). There were no significant differences in
lymphocytes (LYM) (CONTROL 1.59 2.39 109/L,
COVIDposRT-PCRneg 1.11 1.16 109/L, P¼ 0.167) or
white cell count (WCC) (CONTROL; 11.6 6.5 109/L,
COVIDposRT-PCRneg; 11.2 6.6 109/L, P¼ 0.714) or
any other blood test (P> 0.075). Death during admis-
sion was significantly higher (P< 0.0001) in the
COVIDposRT-PCRneg group (n¼ 15/51, 29%) com-
pared to CONTROL (n¼ 11/186, 6%) despite the
COVIDposRT-PCRneg group being significantly
younger (COVIDposRT-PCRneg; 61.8 20.4 years,
CONTROL; 68.9 19.4 years) (P¼ 0.027).
In comparing COVIDposRT-PCRneg patients
with COVIDposRT-PCRpos patients, there were no
Table 2. A comparison of blood test results for all patients referred to General Internal Medicine with a potential diagnosis of
COVID-19 who were ultimately diagnosed with COVID-19 (COVID) or another diagnosis (CONTROL).
COVID (SD) CONTROL (SD) P value Sensitivity Index AUC
Haemoglobin (g/l) 129 (23) 133 (89) 0.582
White cell count (109/L) 8.1 (4.8) 11.6 (6.5) <0.0001**** 0.61 0.69
Platelets (1012/L) 229 (105) 265 (99) 0.0008*** 0.34 0.61
Neutrophils (109/L) 6.4 (4.6) 9.1 (5.7) <0.0001**** 0.51 0.68
Lymphocytes (109/L) 0.9 (0.7) 1.6 (2.4) 0.0001*** 0.38 0.62
Urea (mmol/L) 8.9 (11.3) 7.9 (5.5) 0.279
Creatinine (mmol/L) 96 (86) 85 (62) 0.136
C-reactive protein (mg/L) 96 (82) 84 (102) 0.188
Albumin (g/L) 40 (6.3) 41 (5.4) 0.336
Alkaline Phosphatase (U/L) 98 (83) 117 (120) 0.082
Alanine transaminase (U/L) 49 (52) 51 (142) 0.860
Bilirubin (mmol/L) 12 (10) 15 (16) 0.073
Creatinine kinase (U/L) 294 (538) 197 (449) 0.131
High Sensitivity Troponin I (ng/L) 273.8 (2150) 284.3 (2282) 0.968
D-dimer (ug/L) 2833 (9722) 2378 (3913) 0.686
Aspartate aminotransferase (U/L) 63 (58) 54 (61) 0.407
Lactate dehydrogenase (U/L) 620 (269) 475 (232) <0.0001**** 0.58 0.68
Ferritin (mg/L) 937(1015) 384 (628) <0.0001**** 0.66 0.74
SARS-CoV-2 RT-PCR (detected, %) 76 0.5 <0.0001**** 0.89
Positive blood culture (positive, %) 4 17 0.001**
AUC: area under the curve; SD: standard deviation; SARS-CoV-2 RT-PCR: severe acute respiratory syndrome coronavirus 2 reverse-transcription
polymerase chain reaction.
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significant differences in length of stay (COVIDposRT-
PCRneg; 5.0 5.0, COVIDposRT-PCRpos 6.1 5.3,
P¼ 0.309), sex (62% male in both groups), age
(COVIDposRT-PCRneg; 61.8 20.7,
COVIDposRT-PCRpos; 65.3 17.1, P¼ 0.219), death
during admission (COVIDposRT-PCRneg; 29.4%,
COVIDposRT-PCRpos; 17.3%, P¼ 0.072), any symp-
tom (P >0.097) or radiological manifestations of
COVID-19 (COVIDposRT-PCRneg; 49.7%,
COVIDposRT-PCRpos; 45.1%, P¼ 0.628). However,
there were significantly raised WCC
(COVIDposRT-PCRneg; 11.2 6.6 109/L,
COVIDposRT-PCRpos; 7.1 3.6 109/L, P< 0.0001),
neutrophils (NEU) (COVIDposRT-PCRneg; 9.15
6.5 109/L, COVIDposRT-PCRpos; 5.6 3.4 109/L,
P <0.0001), platelets (PLTS) (COVIDposRT-PCRneg;
265 120 1012/L, COVIDposRT-PCRpos; 219
98 1012/L, P¼ 0.0063) and LYM (COVIDposRT-
PCRneg; 1.1 1.2 109/L, COVIDposRT-PCRpos;
0.9 0.4 109/L, P¼ 0.025) in comparison to the
COVIDposRT-PCRpos. Alkaline phosphatase (ALP)
(COVIDposRT-PCRneg; 145 138U/L, COVIDposRT-
PCRpos; 83 48U/L, P< 0.0001), Bilirubin
(COVIDposRT-PCRneg; 16 13mmol/L,
COVIDposRT-PCRpos; 11 8mmol/L, P¼ 0.038) and
High Sensitivity Troponin I (COVIDposRT-PCRneg;
1058 4536ng/L, COVIDposRT-PCRpos; 52 131ng/
L, P¼ 0.012) were also significantly increased in the
COVIDposRT-PCRneg patients. There was no signifi-
cant difference in FER (COVIDposRT-PCRneg; 985
1344mg/L, COVIDposRT-PCRpos; 925 918mg/L,
P¼ 0.768), CRP (P¼ 0.690) or renal function
(Creatinine, estimated glomerular filtration rate and
Urea; P> 0.315) as well as Albumin (P¼ 0.268), ala-
nine transaminase (ALT) (P¼ 0.213), aspartate amino-
transferase (AST) (P¼ 0.108), d-dimer (P¼ 0.595) and
creatine kinase (P¼ 0.185). The LDH (COVIDposRT-
PCRneg 515 176U/L, COVIDposRT-PCRpos 643
283U/L, P¼ 0.312) and haemoglobin (COVIDposRT-
PCRneg; 121 28 g/L, COVIDposRT-PCRpos; 132
21 g/L, P¼ 0.0042) were significantly lower in the
COVIDposRT-PCRneg patients.
The COVID Combined Blood Test (CCBT)
The COVID and CONTROL groups were compared
to attempt to produce a combined blood test. Only
complete records were used. In comparing COVID
and CONTROL, five blood tests (WCC, NEU,
LYM, LDH and FER) had a sensitivity index >0.35
and the means were significantly different to reject the
null hypothesis (a¼ 0.05) (Table 2).
The output numerical values of the five blood tests
for each patient were linearly combined with weights
that maximized the AUC. The weights were estimated
using a non-parametric stepwise method13 according to
the following procedure:
1. Estimate the AUC from the output values for each
of the five individual blood tests;
2. Order the blood tests according to their estimated
AUC from largest to smallest;
3. Estimate by a search routine the proportion of the
output value of the blood test with the second larg-
est AUC that when added to the output value of the
blood test with the largest AUC produces a maxi-
mum combined AUC;
4. Proceed in this fashion until the blood test with
smallest AUC is included in the linear combination.
The resulting combination is called the COVID
CCBT score. NEU and LDH were found to make neg-
ligible contribution to the weighted combination.
Mathematically, the definition of the CCBT then








where, for example, WCC denotes the numerical value
of a WCC blood test. The negative sign for WCC and
LYM accounts for their negative sensitivity.
The ROC and associated AUC were calculated for
this CCBT, together with the individual ROCs and
AUCs for the constituent blood tests WCC, NEU,
LYM, LDH and FER (Figure 1). The AUC for this
CCBT was 0.79. Figure 2 shows a plot of the sensitivity
and specificity as a function of the output of the CCBT.
For a given patient, the numerical readings for the
three blood tests FER, WCC and LYM are substituted
into equation (2) to provide a CCBT score. With ref-
erence to Figure 2, a threshold CCBT value is chosen
corresponding to the selected pair of sensitivity and
specificity values. The decision COVID/non-COVID
is made according to whether the calculated CCBT
score lies above or below the threshold. We have
used a CCBT threshold of –0.8 to exemplify this in
terms of sensitivity and specificity, where <–0.8
was CCBT negative and 5–0.8 was CCBT positive
(Table 3).
Blood test data were retrospectively collected from a
further 181 patients similarly suspected of COVID-19,
over a further two-week period (9 April to the 24 April
inclusive). Overall, 56% (101/181) were confirmed as
COVID-19 (male; 51.5% age; 71.5 19.4) on discharge
diagnosis of which 32 patients (32%, 32/101) were
COVIDposRT-PCRneg. In comparing this dataset with
the initial 399 patients, in the COVID groups, the
patients were significantly older in the later group
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(P¼ 0.0027) but there was no significant difference in
age (P¼ 0.0843) or mortality (P¼ 0.137). There was no
significant difference in individual blood test results in
comparing full datasets, COVID or CONTROL
groups. The CCBT was tested on this second dataset
resulting in an AUC of 0.78, providing some evidence
of its validation. Sensitivity and specificity can be seen
in Table 3.
Discussion
While there has been an uplift of testing capability for
COVID-19, intermittent delays to hospital diagnosis
remain, particularly in low-resource settings or in the
instance of the patient being COVIDposRT-PCRneg.
While rapid, accurate testing capabilities continue to
evolve, access to these are variable, and accuracy has
only been evaluated in small numbers.14 As hospitals
address the backlog of elective work, coupled with
addressing the non-COVID emergency work, there
will still be the requirement to accurately and rapidly
diagnose COVID-19 patients and quickly transition
patients from ED. Many hospitals, such as ours,
are using a separate ward or facility, for potential
COVID-19 patients to curb the nosocomial transmis-
sion among inpatients, many of whom would be highly
susceptible to severe manifestations of COVID-19.
We found a significantly lower WCC, NEU, PLTS
and LYM in COVID-19 patients and a significantly
higher LDH and FER in comparison to patients who
were not ultimately diagnosed with COVID-19 despite
a clinical suspicion. This may assist in early discrimi-
nation of patients who are more likely to have COVID
so allowing for more accurate quarantine. Our study
used a clinical endpoint for COVID-19 diagnosis so
attempting to capture the 15–20% of patients who
are thought to have COVID-19 but are
COVIDposRT-PCRneg. Using these results, in conjunc-
tion with a sensitivity index, we have been able to
mathematically combine the WCC, LYM and FER
blood test results to attempt to improve clinical
acumen in diagnosing COVID-19. We have named
this the COVID Combined Blood Test. This score
has the potential to improve clinical acumen in diag-
nosing COVID-19 while awaiting formal diagnosis
(Figure 2). Validation shows using a CCBT score of
–0.8 results in a sensitivity of 0.75 and a specificity of
0.73. While this is insufficient to reliably make the diag-
nosis alone, the sensitivity is comparable to a
SARS-CoV-2 RT-PCR swab. This could be used in
conjunction with the clinical presentation and radiolog-
ical investigations to assist the clinician in patient diag-
nosis and flow particularly in low-resource settings,
where the SARS-CoV-2 PCR is suspected to be falsely
negative, or where delays exist.
The addition of radiology and symptoms may
improve the score’s sensitivity and specificity further
although these require a degree of interpretation and
so were not utilized on this first iteration. In retrospect
this was the correct course of action as subsequently
there was the recognition of anosmia and ageusia as
prominent COVID-19 symptoms15 as well as the vari-
able use of CT scanning to improve sensitivity.3 The
CCBT may require further refinement and prospective
Figure 2. The sensitivity and specificity as a function of the
output of the COVID Combined Blood Test (equation (2)) for
the white cell count, lymphocytes and ferritin data sets.
Figure 1. Receiver operator curves (ROC) and area under the
curve (AUC) for the CCBT (COVID Combined Blood Test) and
the individual ROCs and AUCs for WCC (white cell count),
NEU (neutrophils), LYM (lymphocytes), LDH (lactate
dehydrogenase) and FER (ferritin), with SCV2 RT-PCR (severe
acute respiratory syndrome coronavirus 2 reverse-transcription
polymerase chain reaction) included for comparison.
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validation to perform optimally although remained
robust on a further retrospective validating dataset.
We opted not to retrospectively alter the clinical diag-
nosis based on further interpretation of the patient’s
clinical presentation. While this may have improved
confidence in the integrity of the COVID and
CONTROL groups, we felt it had equal potential to
introduce bias.
Studies have assessed blood testing for the purposes
of diagnosis in COVID-19. A study of 207 patients
admitted with symptoms of coronavirus compared
blood tests between those who tested negative and
those testing positive on SARS-CoV-2 RT-PCR.
They did not record symptoms and viral RNA by
RT-PCR was the gold standard. WCCs, NEU and
LYM were significantly lower with AST, ALT and
LDH significantly higher.16 Here they attempted to
use LDH and AST to positively and negatively predict
COVID-19. FER was not recorded. It is interesting
that these largely reflect our results other than for
AST. We also found PLTS and NEU to be significant
which may be due to our larger dataset. A further
Iranian prospective study by Mardani et al.10 of 200
cases assessed the accuracy of routine blood tests only
to evaluate the accuracy of laboratory parameters in
predicting cases with COVID-19 positive RT PCR.
WCC, LYM and albumin were significantly lower in
RT-PCR positive patients with NEU, CRP, AST
(aspartate transaminase), ALT, LDH and Urea signif-
icantly higher. CRP, ALT, LDH, Urea and NEU all
had an AUC of >0.8. We were unable to reproduce this
and one can only presume a differing patient
population.
This retrospective study has several limitations.
These data are built on secondary care patients who
were referred to the GIM team with a presentation
consistent with COVID-19 which serves as a loosely
defined pre-test probability for the CCBT. These crite-
ria could however be more defined to assist with the
varying incidence of COVID-19 over time. That we did
not compare blood tests to a more reproducible and
predictable end point such as a positive SARS-CoV-2
RT PCR result undoubtedly introduced bias. As we did
not retrospectively interpret the clinical diagnosis, and
with the lack of a gold standard for testing, we cannot
be absolutely confident that all patients in the COVID
group had COVID-19 and that all patients in the
CONTROL group did not have COVID-19.
However, we wanted to try and capture this diagnosti-
cally challenging group of RT-PCR negative COVID-
19 patients. We considered that patients who were
COVIDposRT-PCRneg would likely only be diagnosed
as such based on a typical presentation and radiologi-
cal findings. While this was the case in 68% of patients,
these initial diagnostic data were only captured peri-
admission and therefore did not account for repeated
SARS-CoV-2 testing, radiological investigations per-
formed after 48 h, close contact with known
SARS-CoV-2-infected persons, further collateral histo-
ry, or symptoms such as anosmia which, at that
time, had not been absolutely determined. While
these data would have been used to form the discharge
diagnosis it did not inform thinking peri-admission.
Furthermore, while we made every effort to exclude
nosocomial spread, this also cannot be excluded abso-
lutely in this group particularly in patients with repeat
positive PCR diagnosis 48 h after admission. We could
have improved the credibility of a COVID-19 diagnosis
in this important group with an independent panel of
clinicians retrospectively judged the veracity of the dis-
charge diagnoses.
The significant differences in blood test results for
COVIDposRT-PCRneg and COVIDposRT-PCRpos can
potentially be explained by a false-positive diagnosis
of the COVIDposRT-PCRneg patients as having
COVID-19. It is possible however that the patients
who were thought to have COVID-19 but were
COVIDposRT-PCRneg merely presented later, so had
cleared the virus from their nasopharyngeal tract, but
were temporally more likely to be suffering COVID-19
related complications in keeping with the relative leu-
cocytosis, neutrophilia, thrombocytosis, liver function
tests and troponin in the COVIDposRT-PCRneg group.
That we did not account for when the patients became
symptomatic is a further limitation. These data suggest
that in COVIDposRT-PCRneg patients FER is the most
Table 3. The sensitivity, specificity of the CCBT (equation (2)), in comparison to the SARS-CoV-2 RT-PCR on a validating cohort of
181 patients in comparison of 399 patients.
COVID-19 diagnosis
Dataset Test True positives True negatives False positives False negatives Sensitivity Specificity
Initial data
(n¼ 399)
CCBT 127 57 34 23 0.85 0.63
SARS-CoV-2 RNA 122 91 0 28 0.81 1.00
Validation data
(n¼ 181)
CCBT 64 44 15 24 0.73 0.75
SARS-CoV-2 RNA 61 59 0 27 0.69 1.00
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useful discriminating blood test. FER must however be
interpreted in the context of sex, iron status and pre-
morbid disease (particular liver disease) but can also be
raised in other inflammatory and infective conditions
as an acute phase protein. Finally, it is equally plausi-
ble that there was an anchor bias in the CONTROL
group to a negative SARS-CoV-2-RT-PCR result lead-
ing to a false-negative diagnosis and so obscuring the
comparison between COVID and CONTROL. For
instance, 12% of the CONTROL group had radiolog-
ical findings in keeping with COVID-19 but were ulti-
mately not thought to have had COVID-19. This
potentially could have been further granulated if we
collected the final discharge diagnosis of the
CONTROL group rather than just ascertaining that
COVID-19 was not suspected as the cause of the
patient’s presentation. We would consider that while
false positives may be an issue in asymptomatic testing,
in the context of symptomatic hospital admissions
COVIDnegRT-PCRpos is less likely accounting for the
100% specificity of this.
This study also does not address asymptomatic
COVID-19 patients who may not have similar blood
test pictures as those who were hospitalized, as in this
study. This study collected data between the 11 March
and 8 April which saw a rising expansion in COVID-19
cases requiring rapid reorganization of care in NHS
hospitals. As the prevalence increased, the clinician’s
suspicion of COVID-19 is also likely to have increased,
which coupled with enhanced capacity for testing will
have resulted in an inconsistent approach to testing for
SARS-CoV-2 RT-PCR over time with nearly all
patients suspected as having COVID towards the end
of our designated collection period. This introduces
significant bias regarding symptoms. While we saw sig-
nificant differences between COVID and CONTROL,
the clinical suspicion may have been greater in the
COVID group leading to more testing of COVID-19
parameters (e.g., FER, LDH, d-dimers) so confound-
ing the results.
Conclusion
Patients presenting with potential diagnosis of COVID-
19 require rapid accurate diagnosis to halt viral trans-
mission. The diagnosis of COVID-19 can be challeng-
ing due to false negatives and delays in the processing
of SARS-CoV-2 RNA RT-PCR on nasopharyngeal
swab. There are significant differences in WCC,
NEU, PLTS, LYM, LDH and FER in COVID-19
patients in comparison to patients where there is a clin-
ical suspicion, but who are ultimately not diagnosed
with COVID-19. These can be used, in conjunction
with radiology and symptoms, to assist in the diagno-
sis. This is of particular use in a low-resource setting or
where there are delays to definitive diagnosis. FER
appears to be the most reliable blood marker and
may be of particular use where there remains a clinical
suspicion of COVID-19 despite a negative SARS-CoV-
2 RT-PCR. It is possible to combine standard blood
test results (WCC, LYM and FER) with a sensitivity
comparable to SARS-CoV-2 RT-PCR, with the poten-
tial to assist in diagnosing COVID-19, and we have
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